Aerie Pharmaceuticals (AERI) has risen sharply, recording gains of 92.55% in the past 4 weeks. However, the stock has corrected -3.4% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 93.59% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 27.32% and the 50-Day Moving Average is 64.61%.The 200 Day SMA reached 106.14%
Aerie Pharmaceuticals (NASDAQ:AERI): After opening at $37.95, the stock dipped to an intraday low of $37.34 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $38.58 and the buying power remained strong till the end. The stock closed at $37.74 for the day, a gain of 0.11% for the day session. The total traded volume was 734,572. The stocks close on the previous trading day was $37.74.
Aerie Pharmaceuticals (AERI) : The most positive equity analysts on Aerie Pharmaceuticals (AERI) expects the shares to touch $66, whereas, the least positive believes that the stock will trade at $48 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $52.71 with an expected fluctuation of $6.34 from the mean.
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Companys primary product candidates, triple-action Rhopressa and quadruple-action Roclatan, are once-daily eye drops. The Companys product candidate, once-daily, quadruple-action Roclatan, is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET), which are both biochemical targets for lowering intraocular pressure (IOP). The Companys Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533, its second-generation ROCK/NET inhibitor.